zalcitabine has been researched along with AIDS Seroconversion in 28 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 25 (89.29) | 18.2507 |
| 2000's | 2 (7.14) | 29.6817 |
| 2010's | 1 (3.57) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Colan, SD; Mittleman, MA; Oleske, JM; Patel, K; Seage, GR; Van Dyke, RB | 1 |
| Cauda, R; Donelli, G; Landay, AL; Lucia, MB; Malorni, W; Ortona, L | 1 |
| Daniel, MJ; Donn, KH; Evans, GL; Hall, ST; Harker, AJ; Hussey, EK | 1 |
| Craib, KJ; Hogg, RS; Montaner, JS; O'Shaughnessy, MV; Schechter, MT; Strathdee, SA | 1 |
| Evans, GL; Harker, AJ; Hawley, AE; Morris, DM | 1 |
| Arduino, JM; Chung, R; Crumpacker, CS; Hammer, SM; Japour, AJ; Lane, J; Mayers, DL; McLeod, GX; Reichman, R; Wagner, KF | 1 |
| Chou, TC; Hirsch, MS; Merrill, DP; Moonis, M | 1 |
| Boucher, CA; Cammack, N; Hill, A; Ingrand, D; Loveday, C; Robert, C; Weber, J | 1 |
| Detels, R; Graham, NM; Hoover, DR; Mellors, JW; Park, LP; Phair, JP; Saah, AJ; Stein, DS | 1 |
| Eron, JJ; Hussey, EK; Martin, D; Moore, KH; Mydlow, PK; Raasch, RH; Yuen, GJ | 1 |
| Cooper, DA; Harrigan, PR; Kinghorn, I; Lange, JM; Larder, BA; Lavelle, J; Lefkowitz, L; McKinnis, R; Moore, M; Mulder, JW; Pennington, KN; Ramirez-Ronda, C; Rooney, JF; Schooley, RT; St Clair, M; Steel, H | 1 |
| Massarella, JW; Min, B; Nazareno, LA; Passe, S | 1 |
| Bloor, S; Harrigan, PR; Kemp, SD; Kinghorn, I; Kohli, A; Larder, BA; Nájera, I | 1 |
| Bloor, S; Harrigan, PR; Kemp, SD; Kohli, A; Lange, JM; Larder, BA; Pennington, KN; Schooley, RT; St Clair, MH | 1 |
| Blum, AS; Cornblath, DR; Dal Pan, GJ; Feinberg, J; Mayjo, K; McArthur, JC; Raines, C | 1 |
| Albrecht, H; Fenner, T; Greten, H; Lichtenberg, G; Stellbrink, HJ; Thiele, HG; van Lunzen, J; Zöller, B | 1 |
| Bechtel, LM; Starich, GH; Whitfield, RM | 1 |
| Berthelot, P; Frésard, A; Guglielminotti, C; Lucht, F; Perrot, JL | 1 |
| Kempf-Durepaire, G; Krantz, V; Lang, JM; Nicolle, M; Partisani, M; Rey, D; Schmitt, AC; Schmitt, MP | 1 |
| AbdelHameed, MH; Dorr, A; Griffy, K; Jung, D; Teitelbaum, P | 1 |
| La Seta Catamancio, S; Parker, D; Rusconi, S; Sheridan, F | 1 |
| Arendt, G; Hefter, H; Theisen, A; von Giesen, HJ | 1 |
| Harris, R; Kellagher, A; Moyle, GJ; Walker, M; Warburg, M | 1 |
| Arnó, A; Balaguer, M; Camafort, M; Cervantes, M; Clotet, B; Colomer, J; Gutiérrez, C; Ibáñez, A; Peraire, J; Richart, C; Ruiz, L; Vidal, F; Villalonga, C | 1 |
| Antunes, F; Bouza, E; Harris, R; Moyle, GJ; Smith, D; Walker, M; Warburg, M | 1 |
| Molina, JM | 1 |
| Lane, HC | 1 |
1 review(s) available for zalcitabine and AIDS Seroconversion
| Article | Year |
|---|---|
Current status of therapy for human immunodeficiency virus type 1.
Topics: CD4-CD8 Ratio; CD4-Positive T-Lymphocytes; Didanosine; Drug Resistance; HIV Infections; HIV Seropositivity; HIV-1; Humans; T-Lymphocytes, Helper-Inducer; Zalcitabine; Zidovudine | 1992 |
13 trial(s) available for zalcitabine and AIDS Seroconversion
| Article | Year |
|---|---|
Interspecies scaling and pharmacokinetic parameters of 3TC in humans.
Topics: Animals; Antiviral Agents; Body Weight; Cross-Over Studies; Dogs; HIV Seropositivity; Humans; Infusions, Intravenous; Lamivudine; Male; Rats; Reverse Transcriptase Inhibitors; Species Specificity; Zalcitabine | 1994 |
Phase I/II study of 3TC (lamivudine) in HIV-positive, asymptomatic or mild AIDS-related complex patients: sustained reduction in viral markers. The Lamivudine European HIV Working Group.
Topics: Adult; AIDS-Related Complex; Antigen-Antibody Complex; Antiviral Agents; Dose-Response Relationship, Drug; HIV; HIV Core Protein p24; HIV Infections; HIV Seropositivity; Humans; Lamivudine; Leukocytes, Mononuclear; Male; Polymerase Chain Reaction; Reverse Transcriptase Inhibitors; Viremia; Zalcitabine | 1995 |
Survival in HIV-infected patients who have received zidovudine: comparison of combination therapy with sequential monotherapy and continued zidovudine monotherapy. Multicenter AIDS Cohort Study Group.
Topics: Antiviral Agents; CD4 Lymphocyte Count; Didanosine; Disease Progression; Drug Administration Schedule; Drug Therapy, Combination; HIV Seropositivity; Humans; Longitudinal Studies; Male; Proportional Hazards Models; Zalcitabine; Zidovudine | 1996 |
Pharmacokinetics of lamivudine administered alone and with trimethoprim-sulfamethoxazole.
Topics: Administration, Oral; Adult; Analysis of Variance; Anti-Infective Agents; Antiviral Agents; CD4 Lymphocyte Count; Cross-Over Studies; Dose-Response Relationship, Drug; Drug Interactions; Female; HIV Seropositivity; Humans; Lamivudine; Male; Middle Aged; Reverse Transcriptase Inhibitors; Trimethoprim, Sulfamethoxazole Drug Combination; Zalcitabine | 1996 |
Virologic and immunologic benefits of initial combination therapy with zidovudine and zalcitabine or didanosine compared with zidovudine monotherapy. Wellcome Resistance Study Collaborative Group.
Topics: Adult; Antiviral Agents; CD4 Lymphocyte Count; Didanosine; Disease Progression; Drug Resistance, Microbial; Drug Therapy, Combination; Female; HIV Infections; HIV Seropositivity; HIV-1; Humans; Male; Middle Aged; Phenotype; RNA, Viral; Zalcitabine; Zidovudine | 1996 |
The effect of probenecid on the pharmacokinetics of zalcitabine in HIV-positive patients.
Topics: Administration, Oral; Adult; Antiviral Agents; Cross-Over Studies; Drug Administration Schedule; Drug Interactions; Female; Half-Life; HIV Seropositivity; Humans; Kidney Tubules; Male; Middle Aged; Probenecid; Uricosuric Agents; Zalcitabine | 1996 |
Human immunodeficiency virus type 1 drug susceptibility during zidovudine (AZT) monotherapy compared with AZT plus 2',3'-dideoxyinosine or AZT plus 2',3'-dideoxycytidine combination therapy. The protocol 34,225-02 Collaborative Group.
Topics: Antigens, CD; Antiviral Agents; CD4 Antigens; Coculture Techniques; Didanosine; Drug Resistance, Microbial; Drug Therapy, Combination; Genotype; HeLa Cells; HIV Reverse Transcriptase; HIV Seropositivity; HIV-1; Humans; Lymphocytes; Microbial Sensitivity Tests; Phenotype; Point Mutation; RNA-Directed DNA Polymerase; Zalcitabine; Zidovudine | 1996 |
Low-dose zalcitabine-related toxic neuropathy: frequency, natural history, and risk factors.
Topics: Adult; Cohort Studies; Dose-Response Relationship, Drug; Double-Blind Method; Female; HIV Seropositivity; Humans; Incidence; Male; Middle Aged; Nervous System Diseases; Risk Factors; Sensation Disorders; Survival Analysis; Zalcitabine | 1996 |
Rapid plasma virus and CD4+ T-cell turnover in HIV-1 infection: evidence for an only transient interruption by treatment.
Topics: Adult; Anti-HIV Agents; beta 2-Microglobulin; CD4 Lymphocyte Count; Double-Blind Method; Drug Therapy, Combination; Female; HIV Core Protein p24; HIV Seropositivity; HIV-1; Humans; Kinetics; Male; RNA, Viral; Saquinavir; Viral Load; Zalcitabine; Zidovudine | 1996 |
The pharmacokinetics and safety profile of oral ganciclovir combined with zalcitabine or stavudine in asymptomatic HIV- and CMV-seropositive patients.
Topics: Administration, Oral; Anti-HIV Agents; Antiviral Agents; Area Under Curve; Cross-Over Studies; Cytomegalovirus Retinitis; Drug Interactions; Female; Ganciclovir; HIV Seropositivity; Humans; Male; Stavudine; Zalcitabine | 1999 |
Therapeutic effects of nucleoside analogues on psychomotor slowing in HIV infection.
Topics: Adult; Anti-HIV Agents; Central Nervous System Diseases; Didanosine; Drug Therapy, Combination; Female; HIV Infections; HIV Seropositivity; HIV-1; Humans; Lamivudine; Male; Middle Aged; Motor Skills; Stavudine; Zalcitabine; Zidovudine | 2001 |
Zidovudine monotherapy versus zidovudine plus zalcitabine combination therapy in HIV-positive persons with CD4 cell counts 300-500 cells/mm3: a double-blind controlled trial. The M50003 Study Group Coordinating and Writing Committee.
Topics: Adult; Anti-HIV Agents; CD4 Lymphocyte Count; Double-Blind Method; Drug Therapy, Combination; Female; HIV Seropositivity; Humans; Male; Middle Aged; Quality of Life; Zalcitabine; Zidovudine | 1997 |
[Efficacy and tolerance of dideoxynucleosides in HIV infection].
Topics: Acquired Immunodeficiency Syndrome; HIV Seropositivity; Humans; Zalcitabine; Zidovudine | 1992 |
14 other study(ies) available for zalcitabine and AIDS Seroconversion
| Article | Year |
|---|---|
The impact of HAART on cardiomyopathy among children and adolescents perinatally infected with HIV-1.
Topics: Adolescent; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Cardiomyopathies; Cardiotonic Agents; CD4 Lymphocyte Count; Child; Child, Preschool; Cohort Studies; Digoxin; Female; Follow-Up Studies; HIV Seropositivity; Humans; Infant; Infectious Disease Transmission, Vertical; Male; Pregnancy; Prenatal Exposure Delayed Effects; Proportional Hazards Models; Prospective Studies; Treatment Outcome; United States; Zalcitabine; Zidovudine | 2012 |
Transmembrane P-glycoprotein (P-gp/P-170) in HIV infection: analysis of lymphocyte surface expression and drug-unrelated function.
Topics: Adult; Antiviral Agents; ATP Binding Cassette Transporter, Subfamily B, Member 1; Cells, Cultured; Didanosine; Female; HIV Seropositivity; Humans; Immunophenotyping; Interleukin-2; Lymphocyte Activation; Lymphocytes; Male; Phytohemagglutinins; Zalcitabine; Zidovudine | 1995 |
Lower socioeconomic status and shorter survival following HIV infection.
Topics: Acquired Immunodeficiency Syndrome; Adult; British Columbia; CD4 Lymphocyte Count; Cohort Studies; Didanosine; Health Services; HIV Infections; HIV Seropositivity; Homosexuality, Male; Humans; Income; Male; Pneumonia, Pneumocystis; Regression Analysis; Socioeconomic Factors; Survival Rate; Zalcitabine; Zidovudine | 1994 |
High-performance liquid chromatographic assay for 2'-deoxy-3'-thiacytidine in human serum.
Topics: Antiviral Agents; Autoanalysis; Chromatography, High Pressure Liquid; Dideoxynucleosides; HIV Seropositivity; Hot Temperature; Humans; Lamivudine; Quality Control; Sensitivity and Specificity; Zalcitabine | 1994 |
Dideoxynucleoside resistance emerges with prolonged zidovudine monotherapy. The RV43 Study Group.
Topics: Acquired Immunodeficiency Syndrome; AIDS-Related Complex; Didanosine; Drug Resistance, Microbial; HIV Seropositivity; HIV-1; Humans; Leukocytes, Mononuclear; Microbial Sensitivity Tests; Time Factors; Zalcitabine; Zidovudine | 1994 |
Lamivudine or stavudine in two- and three-drug combinations against human immunodeficiency virus type 1 replication in vitro.
Topics: Antiviral Agents; Drug Combinations; Drug Synergism; HIV Reverse Transcriptase; HIV Seropositivity; HIV-1; Humans; Lamivudine; Reverse Transcriptase Inhibitors; RNA-Directed DNA Polymerase; Stavudine; Virus Replication; Zalcitabine | 1996 |
Significance of amino acid variation at human immunodeficiency virus type 1 reverse transcriptase residue 210 for zidovudine susceptibility.
Topics: Antiviral Agents; Codon; Drug Therapy, Combination; Genetic Variation; HeLa Cells; HIV Reverse Transcriptase; HIV Seropositivity; HIV-1; Humans; Lamivudine; Point Mutation; Polymerase Chain Reaction; Reverse Transcriptase Inhibitors; RNA-Directed DNA Polymerase; Virus Replication; Zalcitabine; Zidovudine | 1996 |
The impact of ethanol and Marinol/marijuana usage on HIV+/AIDS patients undergoing azidothymidine, azidothymidine/dideoxycytidine, or dideoxyinosine therapy.
Topics: Acquired Immunodeficiency Syndrome; Adult; Aged; Alcohol Drinking; Amylases; Anti-HIV Agents; Appetite Stimulants; CD4 Lymphocyte Count; Didanosine; Dronabinol; Drug Therapy, Combination; Female; Follow-Up Studies; HIV Seropositivity; Humans; Liver Function Tests; Male; Marijuana Smoking; Middle Aged; Pancreatitis, Alcoholic; Zalcitabine; Zidovudine | 1997 |
Dramatic cutaneous psoriasis improvement in a patient with the human immunodeficiency virus treated with 2',3'-dideoxy,3'-thyacytidine [correction of 2',3'-dideoxycytidine] and ritonavir.
Topics: Adult; Anti-HIV Agents; HIV Seropositivity; Humans; Male; Psoriasis; Remission Induction; Ritonavir; Zalcitabine | 1997 |
[Weak antiviral effect of changing two nucleoside analogues combined with antiretroviral agents. 3TC and d4T after ZDU and ddi or ddc].
Topics: Anti-HIV Agents; CD4 Lymphocyte Count; Didanosine; Drug Therapy, Combination; Female; HIV Seropositivity; HIV-1; Humans; Lamivudine; Male; Retrospective Studies; Stavudine; Viral Load; Zalcitabine; Zidovudine | 1998 |
A genotypic analysis of patients receiving Zidovudine with either Lamivudine, Didanosine or Zalcitabine dual therapy using the LiPA point mutation assay to detect genotypic variation at codons 41, 69, 70, 74, 184 and 215.
Topics: Anti-HIV Agents; Codon; Didanosine; Drug Resistance, Microbial; Drug Resistance, Multiple; Drug Therapy, Combination; Genotype; HIV Infections; HIV Seropositivity; HIV-1; Humans; Lamivudine; Nucleic Acid Hybridization; Point Mutation; Reverse Transcriptase Inhibitors; RNA-Directed DNA Polymerase; Zalcitabine; Zidovudine | 2000 |
Safety and activity of zalcitabine and zidovudine combination in HIV-positive people with CD4 cell counts < or = 300 cells/mm3. The Roche M50002 Study Group.
Topics: Adult; Anti-HIV Agents; CD4 Lymphocyte Count; Drug Therapy, Combination; Female; HIV Seropositivity; Humans; Male; Middle Aged; Zalcitabine; Zidovudine | 1996 |
Immunological and virological activity of zalcitabine and zidovudine in combination in HIV-positive people with CD4 cell counts of between 200-500 cells/mm3.
Topics: Anti-HIV Agents; CD4 Lymphocyte Count; Drug Therapy, Combination; HIV Seropositivity; Humans; RNA, Viral; Zalcitabine; Zidovudine | 1997 |
Potent new AIDS drugs underscore promise of combination therapy.
Topics: Acquired Immunodeficiency Syndrome; Antiviral Agents; CD4 Lymphocyte Count; Drug Approval; Drug Resistance; Drug Therapy, Combination; HIV Infections; HIV Protease Inhibitors; HIV Seropositivity; Humans; Isoquinolines; Lamivudine; Quinolines; Saquinavir; United States; United States Food and Drug Administration; Zalcitabine; Zidovudine | 1996 |